1. Introduction
===============

Acute coronary syndrome (ACS) patients have a wide spectrum of risks for subsequent cardiovascular (CV) causes of morbidity and mortality.^\[[@R1]\]^ Myocardial revascularization, especially percutaneous coronary intervention (PCI), is deemed one of the most effective therapeutic methods for reducing risk of death and improving the prognosis of ACS patients. However, even when treated with PCI and guideline-directed medical therapy, patients with a definite diagnosis of ACS are still at increased risk of adverse CV events.^\[[@R2]\]^ Accordingly, accurate and early identification of such patients at high CV risk would facilitate better clinical management in the future. Unfortunately, there is still a lack of simple and convenient risk assessment tools for predicting adverse CV events in ACS patients undergoing PCI.

The CHADS~2~ (**C**ardiac failure; **H**ypertension; **A**ge ≥75 years; **D**iabetes; previous **S**troke or transient ischemic attack \[TIA\] \[doubled\]) and CHA~2~DS~2~-VASc (**C**ardiac failure; **H**ypertension; **A**ge ≥ 75 years \[doubled\]; **D**iabetes; previous **S**troke or TIA \[doubled\]; **V**ascular disease; **A**ge 65--74 years; and **S**ex category) scores were initially developed to assess risk of stroke or systemic embolism and to guide antithrombotic therapy in patients with atrial fibrillation (AF).^\[[@R3],[@R4]\]^ In fact, most of the variables in these 2 scoring systems are also important risk factors of atherosclerotic CV diseases independent of the cardioembolic pathway; therefore, it is assumed that such scoring systems might have important applications in predicting a wider range of pathophysiologically related CV events beyond the conventional scope of AF.^\[[@R5]\]^ Indeed, the CHADS~2~ and CHA~2~DS~2~-VASc scoring systems have proved to be valuable for predicting the incidence of nonfatal ischemic events and death in many patient groups, regardless of the presence or absence of AF.^\[[@R5]--[@R18]\]^ Of note, several studies have reported that high CHADS~2~ and CHA~2~DS~2~-VASc scores are associated with a significant increase in long- and short-term adverse CV events in patients with ACS^\[[@R6],[@R7],[@R13]\]^ or in those undergoing PCI^\[[@R8],[@R9],[@R11],[@R12],[@R18]\]^. A previous study found no significant difference between CHADS~2~ and CHA~2~DS~2~-VASc scores in predicting mortality in ACS patients.^\[[@R6]\]^ However, additional components of the CHA~2~DS~2~-VASc score that are not included in the CHADS~2~ score---namely, peripheral artery disease (PAD), myocardial infarction (MI) and female sex---are associated with worse clinical outcomes in ACS patients.^\[[@R19],[@R20]\]^ A recent study demonstrated that the CHA~2~DS~2~-VASc score had better predictive value for clinical outcomes than the CHADS~2~ score.^\[[@R7]\]^ Nevertheless, the usefulness of these scores for predicting adverse events in ACS patients undergoing PCI has not been exclusively and adequately studied.^\[[@R16]\]^

The purpose of this study was twofold:

1.  to investigate the predictive utility of the CHADS~2~ and CHA~2~DS~2~-VASc scores for major adverse CV events (MACE) in ACS patients undergoing PCI; and

2.  to compare the discriminatory performance of the CHA~2~DS~2~-VASc score with that of the GRACE (Global Registry of Acute Coronary Events) hospital discharge risk score (GRACE Score) and SYNTAX (Synergy Between PCI With TAXUS and Cardiac Surgery) Score II (SS II) for MACE.

2. Methods
==========

2.1. Study population
---------------------

We enrolled 998 consecutive patients who were admitted to our CV center, diagnosed with ACS and treated with primary or elective PCI during the period from June 2016 to March 2017 into a prospective registry.^\[[@R21]\]^ ACS was diagnosed according to American College of Cardiology (ACC)/American Heart Association (AHA) guidelines.^\[[@R22],[@R23]\]^ Patients with the following conditions were excluded: death before discharge, prior coronary-artery bypass grafting (CABG), renal dysfunction with creatinine clearance (CrCl) \< 15 mL/min or chronic dialysis, Killip class \> II, New York Heart Association (NYHA) class III/IV and left ventricular ejection fraction (LVEF) \< 30%. Two patients were excluded because of missing follow-up data despite at least 4 separate attempts to contact them. Ultimately, 915 patients were retrospectively identified as eligible and were included in the final analysis.

This study was performed in accordance with the Helsinki Declaration of Human Rights. It was approved by the Ethics Committee of Beijing Anzhen Hospital, Capital Medical University, Beijing, China. The requirement for informed patient consent was waived in view of the retrospective nature of the study.

2.2. Measurements
-----------------

In addition to demographic data, we documented traditional CV risk factors and medication history via a questionnaire. After collection of heparinized plasma samples from the central laboratory of Beijing Anzhen Hospital, we analyzed all laboratory parameters immediately. Cardiac failure was defined as the presence of signs/symptoms of congestive heart failure (CHF), current treatment for CHF or objective evidence of reduced ejection fraction (LVEF \< 40%). Patients with vascular diseases related to the aorta and other arteries than the coronary, accompanied by exercise-related intermittent claudication, revascularization surgery, reduced or absent pulsation, angiographic stenosis of ≥50% or combinations of these characteristics, were identified as having PAD. Patients with previous ischemic stroke or transient ischemic attack were defined as having cerebrovascular accident (CVA). Chronic kidney disease (CKD) was defined as CrCl \< 60 mL/min, which we calculated using the Cockcroft--Gault formula^\[[@R24]\]^ from the patient\'s age, weight and serum creatinine (sCr) concentration recorded on admission. The LVEF used was the lowest of the values recorded before the index PCI.

2.3. PCI procedure
------------------

All patients were given loading doses of aspirin (300 mg) and either clopidogrel (300 mg) or ticagrelor (180 mg) before intervention unless they had already received antiplatelet drugs. Subsequently, all patients were required to take aspirin for lifetime and a P2Y12 inhibitor for at least 1 year after intervention. Coronary angiography and PCI were performed using standard techniques.^\[[@R25]\]^ Treatment strategy, balloon dilatation or stent implantation technique, and choice of a particular balloon or stent were all left to the operator\'s discretion.

2.4. CHADS~2~ and CHA~2~DS~2~-VASc scores
-----------------------------------------

CHADS~2~ and CHA~2~DS~2~-VASc scores were calculated from data collected before discharge according to their respective criteria.^\[[@R3],[@R4]\]^ We calculated CHADS~2~ score by assigning 1 point each for cardiac failure, hypertension, age ≥75 years and diabetes; and 2 points for previous CVA. We calculated CHA~2~DS~2~-VASc score by assigning 1 point each for cardiac failure, hypertension, diabetes, vascular disease (including prior/current MI, PAD or aortic plaque), age 65 to 74 years and female sex; and 2 points each for age ≥75 years and previous CVA. In view of the relationship between these 2 scoring systems and adjusted stroke rate reported in previous studies,^\[[@R3],[@R26]\]^ we divided these 2 scores into low, intermediate and high categories, respectively, as follows: CHADS~2~ scores 0, 1--2, and ≥3; CHA~2~DS~2~-VASc scores ≤1, 2--4, and ≥5.

2.5. GRACE score
----------------

We calculated GRACE Score (<http://www.outcomes-umassmed.org/grace/>), which estimates risk of death or MI within the 6 months following hospital discharge, from a patients'

1.  medical history (age, history of CHF and history of MI);

2.  findings at hospital presentation (resting heart rate, systolic blood pressure \[SBP\] and ST depression in electrocardiogram \[ECG\]); and

3.  findings during hospitalization (initial sCr level, elevated cardiac enzymes and in-hospital PCI).

2.6. SYNTAX score II
--------------------

The SS II has been described in full previously.^\[[@R27]\]^ Briefly, it consists of 2 anatomical variables (SYNTAX Score and left-main disease) and 6 demographic and clinical factors (age, CrCl, LVEF, sex, chronic obstructive pulmonary disease \[COPD\], and PAD). Details are available on the SYNTAX Score website ([www.syntaxscore.com](http://www.syntaxscore.com/)).

2.7. Follow-up and end points
-----------------------------

All patients were followed up at 1 month and then every 6 months after hospital discharge. Trained personnel who were blinded to risk scores obtained information on adverse events via telephone contact with patients or their family members using a standardized questionnaire; the adverse events were then ascertained from a careful review of corresponding medical records. The primary endpoint of the study was incidence of MACE, defined as overall death, nonfatal stroke, nonfatal MI or unplanned repeat revascularization. Death was considered to be of CV cause in origin unless a definite non-CV cause could be identified. Stroke was defined as ischemic cerebral infarction (ICI) with evidence of neurological dysfunction requiring hospitalization and with clinically documented lesions on the brain as shown by computed tomography (CT) or magnetic resonance imaging (MRI). MI was defined as elevated levels of cardiac enzymes, such as cardiac troponin or the MB fraction of creatine kinase, exceeding the upper limit of the normal range with either ischemic symptoms or ECG changes implicating ischemia. The presence of new pathological Q waves in ≥2 contiguous ECG leads was also diagnosed as MI. Within 1 week after the index PCI, only Q-wave MI was adjudicated as MI. Unplanned repeat revascularization was defined as any nonstaged revascularization after the index PCI. Staged revascularization was defined as scheduled revascularization within 90 days after the index PCI without retreatment of a coronary-artery territory that had been treated during the index PCI; or a revascularization status of emergency, urgency or salvage. The most severe endpoint was selected for primary-endpoint analysis if \>1 MACE endpoint occurred during follow-up (death \> stroke \> MI \> revascularization). If \>1 stroke or MI or revascularization occurred, the first stroke, MI or revascularization was selected.

2.8. Statistical analysis
-------------------------

CHADS~2~ and CHA~2~DS~2~-VASc scores were analyzed in 2 ways:

1.  as continuous variables; and

2.  as ordinal variables (low vs intermediate vs high).

Continuous variables with parametric distributions are reported as the mean ± standard deviation (SD) and those with nonparametric distributions are reported as median and interquartile ranges. Categorical variables are reported as numbers and percentages. We analyzed differences in 2 continuous variables using Student\'s *t* test or the Mann--Whitney *U* test. Differences in categorical variables were tested using the chi-square test or Fisher\'s exact test, as appropriate. We constructed survival curves as stratified by baseline CHADS~2~ and CHA~2~DS~2~-VASc scores using the Kaplan--Meier procedure with Mantel--Haenszel logrank testing for significance. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional-hazard regression analyses. Predictors of MACE identified via univariate analysis were tested in the multivariate analysis. We selected variables with a univariable significance level of ≤.10 and excluded those that would have caused internal correlations. Female sex, age, hypertension, diabetes, previous CVA, previous MI, current diagnosis of MI, PAD, and cardiac failure are components of the CHADS~2~ and CHA~2~DS~2~-VASc scores, and we believed these variables would cause internal correlations with the variables of the CHADS~2~ and CHA~2~DS~2~-VASc scores. The validity of the proportionality assumption was verified for all covariates by a visual examination of the log (minus log) curves and a test based on Schoenfeld residuals. The discriminatory performances of the CHA~2~DS~2~-VASc score, GRACE Score and SS II for MACE were all assessed using C-statistics. We compared the discriminatory performance of the CHA~2~DS~2~-VASc score with those of GRACE Score and SS II via DeLong\'s method. Analyses were performed using SPSS version 24.0 (IBM Corp., Armonk, NY) and R software version 3.5.3 (R Foundation for Statistical Computing, Beijing, China). A 2-sided *P*-value \< .05 was considered significant.

3. Results
==========

A total of 915 patients with ACS undergoing PCI were included in the present study. These patients had a mean age of 60 ± 10 years; 23.4% were females. CHADS~2~ and CHA~2~DS~2~-VASc scores of total patients are shown in Figure [1](#F1){ref-type="fig"}A and B, respectively.

![(A) Distribution of CHADS~2~ scores over total number of patients. (B) Distribution of CHA~2~DS~2~-VASc scores over total number of patients.](medi-99-e21321-g001){#F1}

Mean follow-up duration was 918 days. Of the total number of patients, 167 (18.3%) developed MACE, which included 21 (2.3%) deaths, 28 (3.1%) events of nonfatal MI, 148 (16.2%) cases of unplanned repeat revascularization and 11 (1.2%) nonfatal strokes. Of these 167 patients, 17 (1.9%) suffered two, 7 patients (0.8%) suffered three and 2 (0.2%) patients suffered four MACE events.

Patients' baseline demographic and clinical characteristics are presented in Table [1](#T1){ref-type="table"}, stratified by development of MACE. Compared with those without MACE, patients with MACE had higher rates of cardiac failure (12.6 vs 3.9%; *P* \< .001), diabetes (52.7% vs 38.9%; *P* = .001), previous MI (25.7% vs 18.6%; *P* = .036), past PCI (26.3% vs 18.4%; *P* = .021) and PAD (22.8% vs 6.6%; *P* \< .001). Those with MACE also had higher levels of fasting plasma glucose (FPG; *P* \< .001) and glycated hemoglobin A1c (HbA1c; *P* \< .001). LVEF was significantly lower in patients with MACE (*P* = .029). Use of medications did not differ between patients with and without MACE at discharge. Angiographic findings and interventional characteristics of patients are presented in Table [2](#T2){ref-type="table"}, stratified by development of MACE. Compared with those without MACE, patients with MACE had higher rates of multivessel or left-main disease, restenotic lesions, and lesions \> 20 mm long (all *P* ≤ .006).

###### 

Baseline demographic and clinical characteristics of the overall population and after stratification by MACE at follow up.

![](medi-99-e21321-g002)

###### 

Angiographic findings and interventional characteristics of the overall population and after stratification by MACE at follow up.

![](medi-99-e21321-g003)

The rates of MACE among low-, intermediate-, and high-CHADS~2~ score groups were 12.0%, 18.8%, and 27.6%, respectively (*P* = .006; Fig. [2](#F2){ref-type="fig"}, left side). Patients with MACE had significantly higher CHADS~2~ scores than those without, 1.5 (1--2.5) vs 1 (0.5--2; *P* = .001; Fig. [2](#F2){ref-type="fig"}, right side). The rates of MACE among low-, intermediate- and high-CHA~2~DS~2~-VASc score groups were 11.7%, 20.1%, and 29.3%, respectively (*P* \< .001; Fig. [3](#F3){ref-type="fig"}, left side). Patients with MACE had significantly higher CHA~2~DS~2~-VASc scores than those without, 3 (2--4) vs 2 (1--3; *P* \< .001; Fig. [3](#F3){ref-type="fig"}, right side).

![CHADS~2~ scores and rates of MACE. Left: Rates of MACE among low-, intermediate-, and high-CHADS~2~ score groups. Right: CHADS~2~ scores compared between patients with and without MACE. MACE = major adverse cardiovascular events.](medi-99-e21321-g004){#F2}

![CHA~2~DS~2~-VASc scores and rates of MACE. Left: Rates of MACE among low-, intermediate-, and high-CHA~2~DS~2~-VASc score groups. Right: CHA~2~DS~2~-VASc scores compared between patients with and without MACE. MACE = major adverse cardiovascular events.](medi-99-e21321-g005){#F3}

Kaplan--Meier analysis showed that patients with higher CHADS~2~ scores had significantly reduced EFS from MACE (logrank test, *P* = .007; Fig. [4](#F4){ref-type="fig"}, left side). We saw a similar but larger difference in EFS from MACE when we stratified patients by CHA~2~DS~2~-VASc score (logrank test, *P* \< .001; Fig. [4](#F4){ref-type="fig"}, right side). Rates of nonfatal stroke (logrank test, *P* \< .001) were higher in proportion to CHADS~2~ score, but there was no significant difference in rates of overall death (logrank test, *P* = .098), CV death (logrank test, *P* = .082), nonfatal MI (logrank test, *P* = .148) or unplanned repeat revascularization (logrank test, *P* = .237) among the low-, intermediate-, and high-CHADS~2~ score groups. By contrast, incidence of nonfatal stroke (logrank test, P \< .001) and unplanned repeat revascularization (logrank test, *P* = .027) were higher in proportion to CHA~2~DS~2~-VASc score, but there was no significant difference in rates of overall death (logrank test, *P* = .103), CV death (logrank test, *P* = .099) or nonfatal MI (logrank test, *P* = .288) among the low-, intermediate-, and high-CHA~2~DS~2~-VASc score groups.

![Kaplan--Meier unadjusted MACE-free survival rates stratified by CHADS~2~ and CHA~2~DS~2~-VASc score groups at follow-up. MACE = major adverse cardiovascular events.](medi-99-e21321-g006){#F4}

Table [3](#T3){ref-type="table"} shows univariate and multivariate Cox proportional-hazard regression analyses (not including CHADS~2~ or CHA~2~DS~2~-VASc score) for MACE at follow up. In multivariate analysis, PAD, cardiac failure, heart rate on admission and serum levels of triglyceride were all independent predictors of MACE. Table [4](#T4){ref-type="table"} presents univariate and multivariate Cox proportional-hazard regression analyses of CHADS~2~ and CHA~2~DS~2~-VASc scores for MACE at follow-up. CHADS~2~ score was a good predictor of MACE in the univariate analysis; however, in the multivariate analysis it was no longer associated with increased risk of MACE. CHA~2~DS~2~-VASc score used as a continuous variable was independently predictive of MACE (HR, 1.15; 95% CI, 1.04--1.27; *P* = .007). When CHA~2~DS~2~-VASc score was used as an ordinal variable, multivariate analysis showed that compared with the low-score group used as a reference, the HRs of the intermediate- and high-score groups for predicting MACE were 1.52 (95% CI, 1.02--2.27; *P* = .042) and 1.96 (95% CI, 1.10--3.49; *P* = .022), respectively. Since CHA~2~DS~2~-VASc score reflects sex-specific stroke or systemic-embolism risk prediction, sex (male vs female) was subject to post-hoc subgroup analysis for MACE. When the analysis was stratified by sex, we found that a higher CHA~2~DS~2~-VASc score was significantly associated with increased risk of MACE in male patients (adjusted HR 1.20, 95% CI: 1.06--1.35; *P* = .004); however, the similar result did not occur in female patients (adjusted HR 1.10, 95% CI: 0.89--1.36; *P* = .373).

###### 

Cox proportional hazards regression analysis for MACE at follow up.
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###### 

HRs for MACE predicted by the CHADS~2~/CHA~2~DS~2~-VASc scores.
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To further evaluate the utility of CHA~2~DS~2~-VASc score for predicting MACE, we compared its discriminatory performance with those of the GRACE Score and SS II as continuous variables. In receiver operating characteristic (ROC) curve analyses, the CHA~2~DS~2~-VASc score had similar C-statistics for MACE as GRACE Score (C-statistics = 0.614; 95%CI, 0.564--0.663 vs C-statistics = 0.598; 95% CI, 0.550--0.645; *P* = .230) and SS II (C-statistics = 0.614; 95%CI, 0.564--0.663 vs C-statistics = 0.609; 95% CI, 0.566--0.652; *P* = .410).

4. Discussion
=============

The CHADS~2~ and CHA~2~DS~2~-VASc scores were originally developed and validated as predictors of stroke or systemic-embolism risk and as stratification schemes for patients with nonvalvular AF to guide individualized antithrombotic therapy.^\[[@R3],[@R4],[@R28],[@R29]\]^ Our study provides promise that CHA~2~DS~2~-VASc score can also play a role in predicting adverse CV outcomes. The main findings from this study can be summarized as follows: First, univariate analysis showed that CHADS~2~ score was a good predictor of MACE; however, it was no longer statistically significant after multivariate analysis. Second, CHA~2~DS~2~-VASc score independently and strongly predicted MACE in patients with ACS undergoing PCI, suggesting that this scoring system might have a potential role in early risk stratification of such patients. Finally, the discriminatory performance of the CHA~2~DS~2~-VASc score for MACE was comparable with those of GRACE Score and SS II.

The vast majority of CHA~2~DS~2~-VASc score components have been demonstrated to be independent predictors of adverse CV outcomes in ACS patients.^\[[@R2],[@R30]\]^ This was one reason for the association between CHA~2~DS~2~-VASc score and adverse CV events in our study. CHA~2~DS~2~-VASc score is reported to be closely related to vascular endothelial dysfunction (VED) as assessed by brachial-flow--mediated dilation (bFMD) and brachial-ankle pulse wave velocity (baPWV).^\[[@R5]\]^ Adverse CV events such as MI^\[[@R31]\]^ and ischemic stroke^\[[@R32]\]^ have been demonstrated to be commonly pathophysiologically characterized by VED as reflected by reduced bFMD or increased baPWV. VED generally triggers the platelet adhesion and aggregation and the fibrin formation that play critical roles in systemic hypercoagulability.^\[[@R33]\]^ In addition, VED is reported to be significantly associated with CV risk factors such as cardiac failure,^\[[@R34]\]^ hypertension,^\[[@R35]\]^ and diabetes,^\[[@R36]\]^ which are components of the CHA~2~DS~2~-VASc score, and to be one of the key points of not only coronary-plaque vulnerability but also other CV complications such as vascular remodeling.^\[[@R37]\]^ The above-mentioned sequential associations might suggest a potential internal correlation between adverse CV events and CHA~2~DS~2~-VASc score.

The prognostic value of the CHA~2~DS~2~-VASc score has been validated in many different cohorts of patients with or without AF, but evidence for its application in ACS patients undergoing PCI is scarce. A study including 13,422 consecutive ACS patients from the Acute Coronary Syndrome Israeli Surveys (ACSIS) demonstrated that a higher CHA~2~DS~2~-VASc score was associated with increased in-hospital, 30-day and 1-year all-cause mortality, as well as with an increased incidence of 30-day combined endpoints of death, MI and unplanned revascularization.^\[[@R13]\]^ Similar findings were demonstrated in another study including 3184 ACS patients, which showed that a CHA~2~DS~2~-VASc score of ≥2 was associated with a higher rate of MI, stroke and death within 1 year of discharge, compared with a score of \<2.^\[[@R7]\]^ In a recent prospective multicenter registry including 929 patients with AF who were referred for PCI, a high CHA~2~DS~2~-VASc score was found to significantly predict all-cause mortality, MI, repeat revascularization, stent thrombosis, TIA, stroke or other arterial thromboembolism.^\[[@R8]\]^ Interestingly, a study including 1330 non-AF patients undergoing PCI also demonstrated that CHA~2~DS~2~-VASc score could predict the combined endpoints of death, MI, destabilizing symptoms leading to hospitalization and nonfatal stroke after PCI.^\[[@R11]\]^ These reports suggest that CHA~2~DS~2~-VASc score has the potential to predict adverse CV events in ACS patients undergoing PCI. As our study demonstrated, a higher CHA~2~DS~2~-VASc score was associated with increased incidence of MACE. This finding was consistent with the results of several previous studies. An ACS subgroup (n = 7729) analysis of a recent study that included 12,785 patients with PCI showed that the CHA~2~DS~2~-VASc score predicted all-cause mortality and death or nonfatal MI in a significant (*P* \< .001) and graded manner.^\[[@R38]\]^ Similarly, a study including 1729 consecutive patients with ACS undergoing PCI also demonstrated that CHA~2~DS~2~-VASc score was an independent predictor of adverse events including cardiac death, MI, stroke and any urgent coronary revascularization at long-term follow-up.^\[[@R16]\]^ Unfortunately, our study did not demonstrate an independent association between CHADS~2~ score and MACE. A potential explanation for CHADS~2~ score having no prognostic significance in our study, unlike CHA~2~DS~2~-VASc score, is that PAD, as the strongest predicator (HR, 2.01; 95% CI, 1.30--3.13) of MACE in the multivariate Cox proportional-hazard regression analysis (not including CHADS~2~ or CHA~2~DS~2~-VASc score), is not a component of in the CHADS~2~ score. Indeed, PAD is an established risk factor in ACS patients.^\[[@R19]\]^ In the post-hoc subgroup analysis based on sex, we found that a higher CHA~2~DS~2~-VASc score was an independent predictor of MACE in male patients, but no longer in female patients, which may be related to the following reason. In the present study, female patients had similar event rates to male patients (18.2% vs 18.3%), and thus sex was not independently associated with MACE in the overall patient cohort. However, the rates of MACE among low-, intermediate- and high- CHA~2~DS~2~-VASc score groups in female patients were all lower than those among the corresponding groups in male patients (5.9% vs 12.0%; 16.6% vs 21.4%; 28.3% vs 31.0%). In fact, female patients with ACS tend to have a higher CV risk than male patients because they may receive less medical attention and care. Therefore, we speculated that adjusted HR of 1.10 for MACE predicted by CHA~2~DS~2~-VASc score in female patients was not statistically significant due to limited sample size and follow-up time.

We demonstrated that the discriminatory performance of the CHA~2~DS~2~-VASc score for MACE was modest and acceptable. The study by Puurunen et al^\[[@R8]\]^ similarly found that the predictive performance of the CHA~2~DS~2~-VASc score was only modest (C-statistics = 0.57) for all-cause mortality and ischemic events in AF patients after PCI. In a recent retrospective cohort study including 1714 non-AF patients with coronary-artery disease (CAD) undergoing PCI from the SHINANO registry,^\[[@R9]\]^ the discriminatory performance of the CHA~2~DS~2~-VASc score for a composite endpoint including all-cause death, nonfatal MI and ischemic stroke was also shown to be modest (C-statistics = 0.64). In our study, we also demonstrated that the discriminatory performance of the CHA~2~DS~2~-VASc score was not inferior to that of the well-known GRACE Score. The GRACE Score is recommended by current guidelines to help clinicians determine post-discharge prognoses of ACS patients and might therefore be useful in guiding management strategy.^\[[@R39]\]^ The study by Capodanno et al^\[[@R11]\]^ revealed that the discriminatory performance of the GRACE Score (C-statistics = 0.66) was comparable with that of the CHA~2~DS~2~-VASc score (*P* = .15) for a composite ischemic endpoint including overall death, MI, destabilizing symptoms leading to hospitalization and nonfatal stroke in an ACS subgroup analysis of patients without AF undergoing PCI. Based on specific anatomical variables and several clinical comorbidities that were shown to affect mortality in the landmark all-comers SYNTAX trial, SS II was introduced to clinical practice for risk stratification in patients with complex CAD who have undergone revascularization. Recently, a study including 734 ACS patients undergoing PCI from the Special Programme University Medicine (SPUM) and COMFORTABLE AMI cohorts demonstrated that SS II was an independent predictor of death and ischemic events during 1-year follow-up and showed superiority in discriminating risk over conventional SS and GRACE Score for all-cause mortality.^\[[@R40]\]^ Our study is the first to assess the incremental prognostic value of the CHA~2~DS~2~-VASc score versus SS II in ACS patients undergoing PCI. C-statistics for SS II was similar to that for CHA~2~DS~2~-VASc score (0.609 vs 0.614, *P* = .410). Another study including 845 AF patients with coronary stenting reached a similar finding, showing discriminatory performance for adverse CV events (including death, stroke, acute MI, and target lesion revascularization) between CHA~2~DS~2~-VASc score and SS II (C-statistics = 0.54 vs 0.55).^\[[@R12]\]^ Compared with GRACE Score and SS II, CHA~2~DS~2~-VASc score has one great advantage: it provides a fast, simple and low-cost method for general clinicians as well as for cardiologists in risk assessment, requiring neither a calculator nor a computer. Therefore, CHA~2~DS~2~-VASc score may be a more practical scoring system for early risk stratification of patients with ACS undergoing PCI.

4.1. Limitations
----------------

A number of limitations should be noted in our study. First, follow-up information was obtained by telephone contact with patients or their relatives, even though medical records were always reviewed in case of ischemic events. Second, whether the findings from the present study including only Chinese patients can be extrapolated to other ethnic groups will require further studies. Third, all patients in our study had been treated with PCI; therefore, our results are not applicable to patients undergoing CABG or who were treated conservatively. Fourth, since we had excluded patients with prior CABG, renal dysfunction with CrCl \< 15 mL/min or chronic dialysis, Killip class \>II, NYHA class III/IV, or LVEF \< 30%, our results may not be applicable to such patients. Fifth, at each follow-up we recorded medications the patients were taking, and found that medication adjustments according to patients' conditions were frequent, especially 1 year after PCI. In fact, medication adjustments do have an impact on CV outcomes. Unfortunately, we did not include medication adherence in the analysis. Finally, CHADS~2~ and CHA~2~DS~2~-VASc scores do not take into consideration several angiographic variables and admission parameters such as cardiac biomarkers, ECG findings, or hemodynamic status. Nevertheless, differences in outcomes according to CHA~2~DS~2~-VASc score remained independent after multivariate Cox proportional-hazard regression analysis that included available angiographic and clinical characteristics.

5. Conclusions
==============

CHA~2~DS~2~-VASc score, a simple and readily available score, could independently and strongly predict post-discharge outcomes in ACS patients undergoing PCI. Such findings need further independent confirmation in future large-scale studies. The potential role of CHA~2~DS~2~-VASc score in predicting MACE might offer important opportunities to optimize individualized treatment for risk-reduction management.
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